Harvey Jones says the GSK share price has dramatically underperformed FTSE 100 rival AstraZeneca, which has had a stellar run ...

AstraZeneca’s share price has fallen a long way this year, which could mean a bargain to be had, so I ran the key numbers to check if this is the case.

The pharma giant's chief exec Emma Walmsley (pictured) said European nations faced 'tough choices' on investment'.

Curating today’s top interviews from around Bloomberg News. Hear conversations with the biggest names in finance, politics ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

Stock markets diverged Tuesday as investors assessed the impact of tariffs on corporate earnings and digested a report that ...

Some telehealth companies that offered compounded GLP-1s have disappeared altogether. Others are pursuing strategies that ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

Noble reported $874 million in revenue for the first quarter, up from $637 million in the same quarter a year earlier. Shares rose 10%. NXP Semiconductors said it expects revenue and earnings to ...

AstraZeneca CEO Pascal Soriot discusses earnings, the potential trade tariff impact on the business and the outlook for the ...